Every Form 4 that SAB Biotherapeutics, Inc. (SABS) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow SABS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SABS filings page.
SAB Biotherapeutics, Inc. chief medical officer Alexandra Kropotova reported a Form 4 showing a tax-withholding disposition of 988 shares of common stock. These shares were withheld to cover taxes on the vesting of restricted stock units. After this event, she holds 42,308 shares, including 5,150 unvested RSUs.
SAB Biotherapeutics, Inc. chief medical officer Alexandra Kropotova reported a routine tax-related share withholding. On the vesting of restricted stock units, 988 shares of common stock were withheld to satisfy tax obligations, rather than sold in the market. After this disposition, she holds 43,296 shares directly, including 8,743 unvested RSUs, each representing a right to receive one share of common stock.
SAB Biotherapeutics reported that its president and director Eddie Joe Sullivan received a grant of stock options on 02/03/2026. The award covers 3,000,000 options to buy common stock at an exercise price of $4.45 per share under the company’s 2021 Omnibus Equity Incentive Plan, as amended. These options vest over four years, with one quarter vesting on the first anniversary of the grant date and the remaining three quarters vesting in 36 equal monthly installments. Following this grant, Sullivan directly holds 3,000,000 derivative securities in the form of stock options.
SAB Biotherapeutics reported that CEO and director Samuel J. Reich received a grant of stock options on 02/03/2026. The award covers 4,800,000 options to buy common stock at an exercise price of $4.45 per share under the company’s 2021 Omnibus Equity Incentive Plan.
The options vest over four years, with one-quarter vesting on the first anniversary of the grant date and the remaining three-quarters vesting in 36 equal monthly installments. All 4,800,000 options are held directly by Reich and are scheduled to expire on 02/03/2036, aligning his potential compensation with longer-term company performance.
SAB Biotherapeutics reported that its Chief Operating Officer, Christoph Lawrence Bausch, received a grant of stock options. On 02/03/2026, he was awarded options to purchase 1,800,000 shares of common stock at an exercise price of $4.45 per share. These options were granted under the company’s 2021 Omnibus Equity Incentive Plan, as amended. The award vests over four years, with one-quarter vesting on the first anniversary of the grant date and the remaining three-quarters vesting in 36 equal monthly installments thereafter. Following this grant, Bausch holds 1,800,000 stock options directly.
SAB Biotherapeutics reported an insider equity award for its Chief Medical Officer, Alexandra Kropotova. On February 3, 2026, she received a stock option grant covering 2,400,000 shares of common stock under the company’s 2021 Omnibus Equity Incentive Plan.
The option has an exercise price of $4.45 per share. The underlying shares vest over four years: one quarter of the grant vests on the first anniversary of the grant date, and the remaining three quarters vest in 36 equal monthly installments thereafter. Following this grant, she beneficially holds options on 2,400,000 shares, all directly owned.
SAB Biotherapeutics reported a new equity award for its Chief Financial Officer, Lucy To. On 02/03/2026, she received a stock option covering 2,400,000 shares of common stock under the company’s 2021 Omnibus Equity Incentive Plan, as amended.
The option has an exercise price of $4.45 per share. The shares underlying the option vest over four years, with 1/4 vesting on the one-year anniversary of the grant date and the remaining 3/4 vesting in 36 equal monthly installments thereafter. After this grant, she beneficially owns 2,400,000 derivative securities directly.
SAB Biotherapeutics, Inc. granted director Rita Jain a new equity award. On January 5, 2026, she received a stock option to purchase 240,000 shares of common stock at an exercise price of $3.74 per share. This represents her inaugural grant as a member of the company’s Board of Directors.
The option expires on January 5, 2036 and the underlying shares vest in three equal annual installments on January 5, 2027, January 5, 2028, and January 5, 2029. The award was made under SAB Biotherapeutics’ 2021 Omnibus Equity Incentive Plan, as amended, and is held directly by Jain.
SAB Biotherapeutics director David Zaccardelli received a new stock option grant. On January 5, 2026, he was awarded options to purchase 240,000 shares of SAB Biotherapeutics, Inc. common stock at an exercise price of $3.74 per share. The options expire on January 5, 2036 and were granted as his inaugural award for serving on the company’s Board of Directors.
The shares underlying this option vest in three equal annual installments on January 5, 2027, January 5, 2028, and January 5, 2029, and were issued under the company’s 2021 Omnibus Equity Incentive Plan, as amended. After this grant, he beneficially owns 240,000 derivative securities in the form of these options, held directly.
SAB Biotherapeutics, Inc. director Jay S. Skyler reported receiving a stock option grant as part of his 2025 annual compensation for serving on the board. On 12/16/2025, he was granted an option to purchase 150,000 shares of common stock at an exercise price of $3.99 per share.
The option was issued under the company’s 2021 Omnibus Equity Incentive Plan, as amended. The shares underlying this option vest in two equal annual installments on December 16, 2026 and December 16, 2027, meaning the director earns the right to exercise half the options on each of those dates if service conditions are met.
SAB Biotherapeutics, Inc. reported an equity award to director William James Polvino. On December 16, 2025, he received a stock option covering 150,000 shares of common stock at an exercise price of $3.99 per share. This grant represents his 2025 annual compensation as a member of the Board of Directors. The option vests in two equal installments on December 16, 2026 and December 16, 2027, meaning he earns the right to exercise half the option on each of those dates. The award was granted under the company’s 2021 Omnibus Equity Incentive Plan, as amended.
SAB Biotherapeutics, Inc. disclosed that a director received a new stock option grant as part of 2025 board compensation. On December 16, 2025, the director was granted a stock option to purchase 150,000 shares of common stock at an exercise price of $3.99 per share, expiring on December 16, 2035. The filing shows the director beneficially owning 150,000 derivative securities directly after this transaction.
According to the disclosure, this grant represents the director’s 2025 annual grant for board service. The shares underlying the option vest in two equal annual installments on December 16, 2026 and December 16, 2027. The award was made under the company’s 2021 Omnibus Equity Incentive Plan, as amended, which governs how equity-based compensation is issued to eligible participants.
SAB Biotherapeutics, Inc. reported an insider equity award for director Katie Ellias. She received a stock option to buy 150,000 shares of common stock at an exercise price of $3.99 per share, dated December 16, 2025, under the company’s 2021 Omnibus Equity Incentive Plan. The grant is described as her 2025 annual award for service on the Board of Directors.
The shares underlying the option vest in two equal annual installments on December 16, 2026 and December 16, 2027, and the option expires on December 16, 2035. Following this grant, she beneficially owns 150,000 derivative securities directly, all tied to this stock option award.
SAB Biotherapeutics, Inc. reported a new stock option award to one of its directors, Scott Giberson. On 12/16/2025, he received a stock option (right to buy) covering 150,000 shares of the company’s common stock with an exercise price of $3.99 per share, expiring on 12/16/2035.
The filing states this is the director’s 2025 annual grant for service on the Board of Directors. The options vest in two equal annual installments on December 16, 2026 and December 16, 2027, and were granted under SAB Biotherapeutics’ 2021 Omnibus Equity Incentive Plan, as amended.
SAB Biotherapeutics director reports new stock option grant. A member of the Board of Directors received a stock option covering 150,000 shares of SAB Biotherapeutics, Inc. common stock on 12/16/2025 at an exercise price of $3.99 per share. The option expires on 12/16/2035 and represents the director’s 2025 annual equity grant. The underlying shares vest in two equal annual installments on December 16, 2026 and December 16, 2027. The award was granted under the company’s 2021 Omnibus Equity Incentive Plan, as amended, and is held directly by the reporting person.
SAB Biotherapeutics, Inc. reported an insider equity transaction by its Chief Medical Officer, Alexandra Kropotova. On 12/11/2025, 988 shares of common stock were withheld to satisfy tax withholding obligations tied to the vesting of previously granted restricted stock units (RSUs).
After this transaction, Kropotova beneficially owned a total of 44,284 shares of common stock. This amount includes 31,946 shares of common stock and 12,338 shares that remain subject to vesting of RSUs granted under the company’s 2021 Equity Incentive Plan, as amended. Each RSU represents a contingent right to receive one share of common stock.
SAB Biotherapeutics insider conversion increases public float via Sessa Capital. The filing reports that Series B Convertible Preferred Stock held by Sessa Capital (Master), L.P. automatically converted into 1,740,000 common shares at an effective conversion price of $1.75 per underlying share, reflecting conversion of 17,400 preferred shares. After the conversion the Sessa Parties are reported to beneficially own 2,198,457 common shares in aggregate, held indirectly through related entities.
The Preferred Stock was purchased by the Fund for an aggregate price of $39,987,500 under a July 21, 2025 purchase agreement. The filing discloses a 4.99% beneficial ownership cap that limits further conversions that would push the Sessa Parties above that threshold. Andrew Moin is identified as a board director of the issuer and is an Analyst and Partner with the Fund; the reported holdings are described as indirect and subject to the stated ownership limitation.
Sessa Capital reported the automatic conversion of Series B Convertible Preferred Stock into common stock of SAB Biotherapeutics (SABS) on 09/29/2025. The filing shows the Fund received 1,740,000 common shares as a result of converting 17,400 preferred shares at an effective price of $1.75 per share. The Fund originally acquired the preferred shares for an aggregate purchase price of $39,987,500 under a July 21, 2025 purchase agreement. After the conversion, the reporting persons collectively beneficially owned 2,198,457 shares of common stock. The conversion is subject to a 4.99% beneficial ownership limitation that restricts further conversions that would exceed that threshold.
Alexandra Kropotova, Chief Medical Officer of SAB Biotherapeutics, Inc. (ticker: SABSW), reported a routine insider transaction dated 09/19/2025. The Form 4 shows 1,977 shares of common stock were disposed through withholding to satisfy tax obligations on vested restricted stock units (RSUs). Following the transaction, she beneficially owns 45,272 shares, which include 29,340 vested shares and 15,932 RSUs that remain subject to vesting.
The filing is a standard Section 16 disclosure reflecting tax-withholding on RSU vesting rather than an open-market sale or purchase. The form was signed by Ms. Kropotova on 09/22/2025 and does not disclose any derivative transactions or other changes in ownership form.